Please do not repost without consent, reposting will be reported.
New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al
World Diabetes Day Reminder: Medication Is Only One Tool While semaglutide is powerful, diabetes management remains a whole-person journey
The conditions are strict under which this consideration is appropriate
Statements Author contributions ST: Methodology, Conceptualization, Supervision, Investigation, Writing original draft, Software, Resources
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study